MyAverix Finance
SA · Healthcare
Alnylam Pharmaceuticals, Inc. (A1LN34)
Biotechnology
Alnylam Pharmaceuticals, Inc. (A1LN34) is listed on SA in the Healthcare sector. Industry: Biotechnology. As of 2026-03-29, reported market cap is $224.50B, P/E ratio is 138.75, net margin is 8.5%. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for A1LN34
Alnylam Pharmaceuticals, Inc. (A1LN34) — FAQ
What is Alnylam Pharmaceuticals, Inc.'s market cap?
Alnylam Pharmaceuticals, Inc. (A1LN34) has a reported market cap of $224.50B (data as of 2026-03-29).
What is A1LN34's P/E ratio?
The price-to-earnings (P/E) ratio for Alnylam Pharmaceuticals, Inc. (A1LN34) is 138.75 (data as of 2026-03-29).
Does Alnylam Pharmaceuticals, Inc. pay a dividend?
Dividend yield is not available in the current snapshot for Alnylam Pharmaceuticals, Inc. (A1LN34). Check the MyAverix Finance app for the latest dividend data.
What sector is Alnylam Pharmaceuticals, Inc. in?
Alnylam Pharmaceuticals, Inc. (A1LN34) is classified in the Healthcare sector (Biotechnology industry).
What exchange is A1LN34 listed on?
A1LN34 is listed on SA.
What is Alnylam Pharmaceuticals, Inc.'s net margin?
Alnylam Pharmaceuticals, Inc. (A1LN34) reports a net margin of 8.5% (data as of 2026-03-29).
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.